
The Top 5 Biosimilar Articles for the Week of March 24
Number 5: Patients with moderate to severe plaque psoriasis who switched between the adalimumab biosimilar GP2017 and reference adalimumab did not impact immunogenicity, safety, or efficacy following up to 4 switches between both drugs. Number 4: Tendering …